english.prescrire.org > Prescrire International > N°171 - May 2016

n°171

May 2016

Issue Contents
Editorial

Free  Intense pharma lobbying in the EU

p.116
European citizens are the ones to suffer

New Products


Dasabuvir (Exviera°)

p.117-120
Only assessed as part of a difficult-to-manage combination in hepatitis C

Ombitasvir + paritaprevir + ritonavir (Viekirax°)

p.121-122
Hepatitis C: high risk of interactions and serious liver injury

Dalbavancin (Xydalba°)

p.123-125
Severe bacterial infections of the skin: a teicoplanin me-too

INN Common stem: -setron

p.125

Ramucirumab (Cyramza°)

p.126
Gastric cancer: very little efficacy

Adverse Effects


Drug-induced hair loss

p.127-129
Not only cytotoxic agents

Ondansetron and pregnancy: possible congenital heart defects

p.129-130
Beware of 5-HT3 antagonists during pregnancy

Olmesartan: sprue-like enteropathy

p.130-131
Don't wait for regulators to withdraw it from the market

Reviews


Free  Ranibizumab or bevacizumab in AMD?

p.132-133
Informazioni sui Farmaci versus Prescrire

Acute uncomplicated cystitis: what is the role for pivmecillinam?

p.134-135
A useful option

Outlook


Free  New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all

p.136-139

Free  "Orphan" drug status: abuse of incentives

p.138

Masthead


Free  Masthead

p.114

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe